|
Report Date : |
03.03.2014 |
IDENTIFICATION DETAILS
|
Name : |
SANIL PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
103-21, Seongsan 1-dong, Mapo-gu, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
29.06.1998 |
|
|
|
|
Reg. No.: |
105-81-93934 |
|
|
|
|
Legal Form : |
Co., Ltd by Shares |
|
|
|
|
Line of Business : |
Wholesale of Pharmaceuticals |
|
|
|
|
No. of Employees : |
11 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2013
|
Country Name |
Previous Rating (30.06.2013) |
Current Rating (30.09.2013) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SOUTH KOREA - ECONOMIC
OVERVIEW
South Korea over the past four decades has demonstrated
incredible growth and global integration to become a high-tech industrialized economy.
In the 1960s, GDP per capita was comparable with levels in the poorer countries
of Africa and Asia. In 2004, South Korea joined the trillion dollar club of
world economies, and is currently the world's 12th largest economy. Initially,
a system of close government and business ties, including directed credit and
import restrictions, made this success possible. The government promoted the
import of raw materials and technology at the expense of consumer goods, and
encouraged savings and investment over consumption. The Asian financial crisis
of 1997-98 exposed longstanding weaknesses in South Korea's development model
including high debt/equity ratios and massive short-term foreign borrowing. GDP
plunged by 6.9% in 1998, and then recovered by 9% in 1999-2000. Korea adopted
numerous economic reforms following the crisis, including greater openness to
foreign investment and imports. Growth moderated to about 4% annually between
2003 and 2007. Korea's export focused economy was hit hard by the 2008 global
economic downturn, but quickly rebounded in subsequent years, reaching 6.3%
growth in 2010. The US-South Korea Free Trade Agreement was ratified by both
governments in 2011 and went into effect in March 2012. Throughout 2012 and
2013 the economy experienced sluggish growth because of market slowdowns in the
United States, China, and the Eurozone. The administration in 2014 is likely to
face the challenge of balancing heavy reliance on exports with developing
domestic-oriented sectors, such as services. The South Korean economy's long
term challenges include a rapidly aging population, inflexible labor market,
and heavy reliance on exports - which comprise about half of GDP.
|
Source
: CIA |
Basic
|
Company Name |
SANIL PHARMACEUTICAL CO., LTD. |
|
Registered Address |
103-21, Seongsan 1-dong, Mapo-gu, Seoul, Korea |
|
Zip Code |
121-844 |
|
Tel |
+82-2-323-1236 |
|
Fax |
+82-2-323-1253 |
|
E-mail |
ssanilpharm@yahoo.co.kr |
|
Trading Address |
16, World Cup buk-ro 15-gil, Mapo-gu, Seoul, Korea 103-21, Seongsan 1-dong, Mapo-gu, Seoul, Korea |
|
Tel |
+82-2-323-1236 |
|
Fax |
+82-2-323-1253 |
|
Type |
Import |
|
Industry |
Wholesale of Pharmaceuticals |
|
Main Business |
Pharmaceuticals, Cosmetics, Chemicals |
|
Established (mm/dd/yyyy) |
06/29/1998 |
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
|
Sell |
Pharmaceuticals |
|
Sell |
Cosmetics |
|
Sell |
Chemicals |
|
Name |
Kim Jung-Hyun |
|
Address |
Suite 404-802, 79, Norumok-ro,
Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea |
|
Date of Birth |
07/18/1956 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
210,000,000 |
|
Employees |
11 |
|
Formation |
Co., Ltd by Shares |
|
Bank Details |
Kookmin Bank-Sungsan Dong Branch |
|
Corporate Registered No. |
110111-1560550 |
|
Business Registered No. |
105-81-93934 |
|
Permit & Licenses |
N/A |
|
Shareholder Position |
N/A |
|
Company History |
1996 Established as SANIL
PHARMACEUTICAL CO.(Sole Proprietorship) 06/29/1998 Incorporated as the present name |
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
Mr. |
Kim Jung-Hyun |
Male |
Korean |
06/29/1998 |
|
Director |
Mr. |
Kim Kyung-Hyun |
Male |
Korean |
06/29/1998 |
|
Director |
M/S. |
La Kyung-Ok |
Female |
Korean |
06/29/1998 |
Financials
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
2012 |
14,919,000,000 |
9,780,000,000 |
187,000,000 |
|
2011 |
13,959,000,000 |
9,351,000,000 |
478,000,000 |
|
2010 |
14,928,000,000 |
8,477,000,000 |
793,000,000 |
|
2009 |
14,307,000,000 |
7,145,000,000 |
838,000,000 |
|
2008 |
11,274,000,000 |
6,063,000,000 |
355,000,000 |
|
Authorized Capital(KRW) |
840,000,000 |
|
Paid-Up Capital(KRW) |
210,000,000 |
|
Total Issued Shares |
21,000 |
|
Balance Sheet |
|||
|
Unit : Korean Won |
As of 12/31/2012 |
As of 12/31/2011 |
As of 12/31/2010 |
|
Total Assets |
9,780,000,000 |
9,351,000,000 |
8,477,000,000 |
|
Current Assets |
7,863,000,000 |
7,400,000,000 |
6,702,000,000 |
|
-Quick Assets |
- |
- |
- |
|
-Inventories |
- |
- |
- |
|
Fixed Assets |
1,917,000,000 |
1,951,000,000 |
1,775,000,000 |
|
-Investment |
- |
- |
- |
|
-Tangibles |
- |
- |
- |
|
-Intangibles |
- |
- |
- |
|
Total Liabilities |
5,578,000,000 |
5,335,000,000 |
4,940,000,000 |
|
Current Liabilities |
1,526,000,000 |
1,654,000,000 |
1,734,000,000 |
|
Fixed Liabilities |
4,052,000,000 |
3,681,000,000 |
3,206,000,000 |
|
Capital Stock |
210,000,000 |
210,000,000 |
210,000,000 |
|
Capital Surplus |
- |
- |
- |
|
Profit Surplus |
- |
- |
- |
|
Capital Adjustment |
- |
- |
- |
|
Total Equity |
4,202,000,000 |
4,016,000,000 |
3,537,000,000 |
|
Liab. & Shareholder’s Equity |
9,780,000,000 |
9,351,000,000 |
8,477,000,000 |
|
Income Statement |
|||
|
Unit : Korean Won |
As of 12/31/2012 |
As of 12/31/2011 |
As of 12/31/2010 |
|
Sales |
14,919,000,000 |
13,959,000,000 |
14,928,000,000 |
|
Cost of Sold Goods |
12,549,000,000 |
11,620,000,000 |
12,189,000,000 |
|
Gross Profit |
2,370,000,000 |
2,339,000,000 |
2,739,000,000 |
|
Selling & Admin. Expenses |
1,851,000,000 |
1,456,000,000 |
1,593,000,000 |
|
Operating Income |
519,000,000 |
883,000,000 |
1,146,000,000 |
|
Non-Operating Income |
102,000,000 |
91,000,000 |
159,000,000 |
|
Non-Operating Expenses |
283,000,000 |
375,000,000 |
301,000,000 |
|
Income Before Taxes |
339,000,000 |
599,000,000 |
1,004,000,000 |
|
Income Taxes Expenses |
152,000,000 |
121,000,000 |
211,000,000 |
|
Net Income |
187,000,000 |
478,000,000 |
793,000,000 |
|
Main Products & Services |
Pharmaceuticals, Cosmetics, Chemicals |
|
Competitors |
GEO-YOUNG CORPORATION 421-1, YEONHUI-DONG, SEODAEMUN-GU, SEOUL,
KOREA TEL:+82-2-3662-8222 FAX:+82-2-3141-6492 BONA MEDICAL SUPPLY CO., LTD. 787, JUNG-RI, DONGTAN-MYEON, HWASEONG-SI,
GYEONGGI-DO, KOREA TEL:+82-31-377-8091 FAX:+82-31-377-8095 BOKSAN PHARM. CO., LTD. 825-13, BEOMIL 2-DONG, DONG-GU, BUSAN,
KOREA TEL:+82-51-667-1511 FAX:+82-51-645-2365 |
|
Sales/ Unit :Mil KRW |
2012 |
2011 |
2010 |
|
Export |
|
|
|
|
Domestic |
|
|
|
|
Total |
|
|
|
The Subject imports from New Zealand and
China.
Not Available.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.07 |
|
|
1 |
Rs.103.61 |
|
Euro |
1 |
Rs.85.03 |
INFORMATION DETAILS
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome
financial difficulties seems comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment record
(10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.